Programmed death-ligand 1 (PD-L1) polymorphisms as predictive biomarkers for the development of liver cirrhosis and hepatocellular carcinoma in HCV Egyptian patients
Authors:
Open Access
- 18 October 2022
- journal article
- research article
- Published by Elsevier in Tumour Virus Research
- Vol. 14, 200249
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancerCancer Biomarkers, 2018
- Programmed death-1 ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squamous cell carcinoma in smokersCancer Biomarkers, 2017
- Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinomaHuman Pathology, 2017
- Role of ApoB‐516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibilityJournal of Medical Virology, 2017
- Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer PatientsScientific Reports, 2017
- Variant SNPs at the microRNA complementary site in the B7-H1 3′-untranslated region increase the risk of non-small cell lung cancerMolecular Medicine Reports, 2017
- Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancerGene, 2017
- PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapyScientific Reports, 2016
- A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinomaHuman Genetics, 2013
- Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosisJournal of Hepatology, 2012